CA2068817A1 - Vaccines and methods for their production - Google Patents
Vaccines and methods for their productionInfo
- Publication number
- CA2068817A1 CA2068817A1 CA002068817A CA2068817A CA2068817A1 CA 2068817 A1 CA2068817 A1 CA 2068817A1 CA 002068817 A CA002068817 A CA 002068817A CA 2068817 A CA2068817 A CA 2068817A CA 2068817 A1 CA2068817 A1 CA 2068817A1
- Authority
- CA
- Canada
- Prior art keywords
- virus
- vaccine
- inactivation
- ethylenimine
- propiolactone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 229960005486 vaccine Drugs 0.000 title claims abstract description 83
- 238000000034 method Methods 0.000 title claims abstract description 48
- 238000004519 manufacturing process Methods 0.000 title abstract description 9
- 241000700605 Viruses Species 0.000 claims abstract description 121
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 26
- 230000008569 process Effects 0.000 claims abstract description 24
- 230000000415 inactivating effect Effects 0.000 claims abstract description 19
- 239000003599 detergent Substances 0.000 claims abstract description 9
- 239000002904 solvent Substances 0.000 claims abstract description 6
- 239000003431 cross linking reagent Substances 0.000 claims abstract description 3
- 230000003019 stabilising effect Effects 0.000 claims abstract description 3
- 230000002779 inactivation Effects 0.000 claims description 35
- 239000002671 adjuvant Substances 0.000 claims description 30
- 238000002360 preparation method Methods 0.000 claims description 27
- QRLVDLBMBULFAL-UHFFFAOYSA-N Digitonin Natural products CC1CCC2(OC1)OC3C(O)C4C5CCC6CC(OC7OC(CO)C(OC8OC(CO)C(O)C(OC9OCC(O)C(O)C9OC%10OC(CO)C(O)C(OC%11OC(CO)C(O)C(O)C%11O)C%10O)C8O)C(O)C7O)C(O)CC6(C)C5CCC4(C)C3C2C QRLVDLBMBULFAL-UHFFFAOYSA-N 0.000 claims description 26
- UVYVLBIGDKGWPX-UHFFFAOYSA-N digitonine Natural products CC1C(C2(CCC3C4(C)CC(O)C(OC5C(C(O)C(OC6C(C(OC7C(C(O)C(O)CO7)O)C(O)C(CO)O6)OC6C(C(OC7C(C(O)C(O)C(CO)O7)O)C(O)C(CO)O6)O)C(CO)O5)O)CC4CCC3C2C2O)C)C2OC11CCC(C)CO1 UVYVLBIGDKGWPX-UHFFFAOYSA-N 0.000 claims description 26
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 claims description 25
- UVYVLBIGDKGWPX-KUAJCENISA-N digitonin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)C[C@@H](O)[C@H](O[C@H]5[C@@H]([C@@H](O)[C@@H](O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)CO7)O)[C@H](O)[C@@H](CO)O6)O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O7)O)[C@@H](O)[C@@H](CO)O6)O)[C@@H](CO)O5)O)C[C@@H]4CC[C@H]3[C@@H]2[C@@H]1O)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 UVYVLBIGDKGWPX-KUAJCENISA-N 0.000 claims description 25
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 22
- VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 claims description 19
- 241001465754 Metazoa Species 0.000 claims description 16
- 208000015181 infectious disease Diseases 0.000 claims description 15
- 230000000890 antigenic effect Effects 0.000 claims description 13
- 239000000126 substance Substances 0.000 claims description 13
- 238000012360 testing method Methods 0.000 claims description 13
- 102000004169 proteins and genes Human genes 0.000 claims description 12
- 241000282414 Homo sapiens Species 0.000 claims description 11
- 108090000623 proteins and genes Proteins 0.000 claims description 11
- 230000005847 immunogenicity Effects 0.000 claims description 9
- 210000004027 cell Anatomy 0.000 claims description 8
- 230000028993 immune response Effects 0.000 claims description 8
- OTIXUSNHAKOJBX-UHFFFAOYSA-N 1-(aziridin-1-yl)ethanone Chemical group CC(=O)N1CC1 OTIXUSNHAKOJBX-UHFFFAOYSA-N 0.000 claims description 7
- 210000002845 virion Anatomy 0.000 claims description 7
- 238000003556 assay Methods 0.000 claims description 6
- 230000002458 infectious effect Effects 0.000 claims description 6
- 239000002245 particle Substances 0.000 claims description 6
- 238000011282 treatment Methods 0.000 claims description 6
- 230000003612 virological effect Effects 0.000 claims description 6
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 claims description 5
- 238000010171 animal model Methods 0.000 claims description 5
- 239000012228 culture supernatant Substances 0.000 claims description 4
- 238000003752 polymerase chain reaction Methods 0.000 claims description 4
- 230000002441 reversible effect Effects 0.000 claims description 4
- 230000006641 stabilisation Effects 0.000 claims description 4
- 238000002965 ELISA Methods 0.000 claims description 3
- 229930006000 Sucrose Natural products 0.000 claims description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 3
- 108020000999 Viral RNA Proteins 0.000 claims description 3
- 229940099352 cholate Drugs 0.000 claims description 3
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 239000012530 fluid Substances 0.000 claims description 3
- 238000003119 immunoblot Methods 0.000 claims description 3
- 230000001566 pro-viral effect Effects 0.000 claims description 3
- 238000000746 purification Methods 0.000 claims description 3
- 239000005720 sucrose Substances 0.000 claims description 3
- 238000002255 vaccination Methods 0.000 claims description 3
- 101000637771 Homo sapiens Solute carrier family 35 member G1 Proteins 0.000 claims description 2
- 108010061833 Integrases Proteins 0.000 claims description 2
- 238000004458 analytical method Methods 0.000 claims description 2
- 238000004113 cell culture Methods 0.000 claims description 2
- 102000053339 human SLC35G1 Human genes 0.000 claims description 2
- 210000005259 peripheral blood Anatomy 0.000 claims description 2
- 239000011886 peripheral blood Substances 0.000 claims description 2
- 230000000644 propagated effect Effects 0.000 claims description 2
- 208000008864 scrapie Diseases 0.000 claims description 2
- 230000004083 survival effect Effects 0.000 claims description 2
- 102100034343 Integrase Human genes 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
- 229940124718 AIDS vaccine Drugs 0.000 abstract description 4
- 229960000380 propiolactone Drugs 0.000 description 34
- 241000725303 Human immunodeficiency virus Species 0.000 description 31
- 230000000694 effects Effects 0.000 description 14
- 229930182490 saponin Natural products 0.000 description 11
- 235000017709 saponins Nutrition 0.000 description 11
- 150000007949 saponins Chemical class 0.000 description 10
- 241000710198 Foot-and-mouth disease virus Species 0.000 description 9
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 9
- 229940031626 subunit vaccine Drugs 0.000 description 9
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 7
- 241000700199 Cavia porcellus Species 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- 102000039446 nucleic acids Human genes 0.000 description 7
- 108020004707 nucleic acids Proteins 0.000 description 7
- 150000007523 nucleic acids Chemical class 0.000 description 7
- ALRHLSYJTWAHJZ-UHFFFAOYSA-N 3-hydroxypropionic acid Chemical compound OCCC(O)=O ALRHLSYJTWAHJZ-UHFFFAOYSA-N 0.000 description 6
- 235000019256 formaldehyde Nutrition 0.000 description 6
- 229960003971 influenza vaccine Drugs 0.000 description 6
- 208000030507 AIDS Diseases 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000036039 immunity Effects 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 3
- 108090000288 Glycoproteins Proteins 0.000 description 3
- 102000003886 Glycoproteins Human genes 0.000 description 3
- 241000713311 Simian immunodeficiency virus Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 229940031551 inactivated vaccine Drugs 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 210000004779 membrane envelope Anatomy 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 241000712461 unidentified influenza virus Species 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- UGXDVELKRYZPDM-XLXQKPBQSA-N (4r)-4-[[(2s,3r)-2-[[(2r)-2-[(2r,3r,4r,5r)-2-acetamido-4,5,6-trihydroxy-1-oxohexan-3-yl]oxypropanoyl]amino]-3-hydroxybutanoyl]amino]-5-amino-5-oxopentanoic acid Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H]([C@H](O)C)NC(=O)[C@@H](C)O[C@@H]([C@H](O)[C@H](O)CO)[C@@H](NC(C)=O)C=O UGXDVELKRYZPDM-XLXQKPBQSA-N 0.000 description 2
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 229940033330 HIV vaccine Drugs 0.000 description 2
- 102100034349 Integrase Human genes 0.000 description 2
- 206010023927 Lassa fever Diseases 0.000 description 2
- 241000713666 Lentivirus Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000282579 Pan Species 0.000 description 2
- 241000711798 Rabies lyssavirus Species 0.000 description 2
- 230000024932 T cell mediated immunity Effects 0.000 description 2
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 2
- UZQJVUCHXGYFLQ-AYDHOLPZSA-N [(2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-4-[(2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-6-(hy Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)CC(O)[C@]1(CCC(CC14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZQJVUCHXGYFLQ-AYDHOLPZSA-N 0.000 description 2
- 230000000240 adjuvant effect Effects 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 229940037003 alum Drugs 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 230000002434 immunopotentiative effect Effects 0.000 description 2
- 230000003308 immunostimulating effect Effects 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- CKFGINPQOCXMAZ-UHFFFAOYSA-N methanediol Chemical compound OCO CKFGINPQOCXMAZ-UHFFFAOYSA-N 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 229960001539 poliomyelitis vaccine Drugs 0.000 description 2
- 229920001983 poloxamer Polymers 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 238000007142 ring opening reaction Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000003892 spreading Methods 0.000 description 2
- 230000007480 spreading Effects 0.000 description 2
- 229940031439 squalene Drugs 0.000 description 2
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- -1 triterpene glycoside saponin Chemical class 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- DEPDDPLQZYCHOH-UHFFFAOYSA-N 1h-imidazol-2-amine Chemical compound NC1=NC=CN1 DEPDDPLQZYCHOH-UHFFFAOYSA-N 0.000 description 1
- WJAXXWSZNSFVNG-UHFFFAOYSA-N 2-bromoethanamine;hydron;bromide Chemical compound [Br-].[NH3+]CCBr WJAXXWSZNSFVNG-UHFFFAOYSA-N 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- 101100099490 Alkalihalobacillus halodurans (strain ATCC BAA-125 / DSM 18197 / FERM 7344 / JCM 9153 / C-125) thiY gene Proteins 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 230000007035 DNA breakage Effects 0.000 description 1
- 101710121417 Envelope glycoprotein Proteins 0.000 description 1
- 241000713800 Feline immunodeficiency virus Species 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 229940124873 Influenza virus vaccine Drugs 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 241000282553 Macaca Species 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 108010001267 Protein Subunits Proteins 0.000 description 1
- 102000002067 Protein Subunits Human genes 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 206010037742 Rabies Diseases 0.000 description 1
- 206010051497 Rhinotracheitis Diseases 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 239000004133 Sodium thiosulphate Substances 0.000 description 1
- 108010008038 Synthetic Vaccines Proteins 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 1
- 208000010094 Visna Diseases 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 159000000013 aluminium salts Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000001949 anaesthesia Methods 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 238000012769 bulk production Methods 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 239000002812 cholic acid derivative Substances 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- PSLWZOIUBRXAQW-UHFFFAOYSA-M dimethyl(dioctadecyl)azanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC PSLWZOIUBRXAQW-UHFFFAOYSA-M 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 230000001516 effect on protein Effects 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 125000005639 glycero group Chemical group 0.000 description 1
- 150000002338 glycosides Chemical group 0.000 description 1
- 230000033687 granuloma formation Effects 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 150000002402 hexoses Chemical class 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 230000008348 humoral response Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000001841 imino group Chemical group [H]N=* 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 231100000092 inhalation hazard Toxicity 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- BWHLPLXXIDYSNW-UHFFFAOYSA-N ketorolac tromethamine Chemical compound OCC(N)(CO)CO.OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 BWHLPLXXIDYSNW-UHFFFAOYSA-N 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 229940124590 live attenuated vaccine Drugs 0.000 description 1
- 229940023012 live-attenuated vaccine Drugs 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 238000010915 one-step procedure Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- WCNLCIJMFAJCPX-UHFFFAOYSA-N pethidine hydrochloride Chemical compound Cl.C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 WCNLCIJMFAJCPX-UHFFFAOYSA-N 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000003495 polar organic solvent Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 208000009305 pseudorabies Diseases 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 229940124551 recombinant vaccine Drugs 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 230000002226 simultaneous effect Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- DHCDFWKWKRSZHF-UHFFFAOYSA-L thiosulfate(2-) Chemical compound [O-]S([S-])(=O)=O DHCDFWKWKRSZHF-UHFFFAOYSA-L 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- STCOOQWBFONSKY-UHFFFAOYSA-N tributyl phosphate Chemical compound CCCCOP(=O)(OCCCC)OCCCC STCOOQWBFONSKY-UHFFFAOYSA-N 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 230000005951 type IV hypersensitivity Effects 0.000 description 1
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 229940125575 vaccine candidate Drugs 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 231100000925 very toxic Toxicity 0.000 description 1
- 230000008957 viral persistence Effects 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/04—Inactivation or attenuation; Producing viral sub-units
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55588—Adjuvants of undefined constitution
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16061—Methods of inactivation or attenuation
- C12N2760/16063—Methods of inactivation or attenuation by chemical treatment
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Telephone Function (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9110808.4 | 1991-05-17 | ||
| GB919110808A GB9110808D0 (en) | 1991-05-17 | 1991-05-17 | Aids vaccine and method for its production |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2068817A1 true CA2068817A1 (en) | 1992-11-18 |
Family
ID=10695252
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002068817A Abandoned CA2068817A1 (en) | 1991-05-17 | 1992-05-15 | Vaccines and methods for their production |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US5698432A (enExample) |
| EP (1) | EP0514199B1 (enExample) |
| JP (1) | JPH05328967A (enExample) |
| KR (1) | KR0149182B1 (enExample) |
| AT (1) | ATE172642T1 (enExample) |
| AU (1) | AU652447B2 (enExample) |
| BR (1) | BR9201848A (enExample) |
| CA (1) | CA2068817A1 (enExample) |
| DE (1) | DE69227400T2 (enExample) |
| ES (1) | ES2127203T3 (enExample) |
| GB (1) | GB9110808D0 (enExample) |
| IE (1) | IE921556A1 (enExample) |
| IN (1) | IN174080B (enExample) |
| NZ (1) | NZ242780A (enExample) |
| SG (1) | SG49763A1 (enExample) |
| ZA (1) | ZA923607B (enExample) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69131427T2 (de) * | 1991-05-28 | 1999-11-25 | Kabushiki Kaisha Toshiba, Kawasaki | Arbeitsvorrichtung |
| AUPN030794A0 (en) | 1994-12-22 | 1995-01-27 | Aruba International Pty Ltd | Discontinuous plasma or serum delipidation |
| DE19520216C2 (de) * | 1995-06-01 | 1997-04-10 | Frey Rainer H | Vakzine zur Prophylaxe und Therapie von AIDS, und Verfahren zur Herstellung |
| US20040053208A1 (en) * | 1995-08-29 | 2004-03-18 | V. I. TECHNOLOGIES, Inc. | Methods to selectively inactivate parasites in biological compositions |
| US6093564A (en) | 1997-10-03 | 2000-07-25 | V.I. Technologies, Inc. | Methods and compositions for the selective modification of nucleic acids |
| US6352695B1 (en) * | 1997-10-03 | 2002-03-05 | V.I. Technologies, Inc. | Methods and compositions for the selective modification of nucleic acids |
| US6617100B2 (en) | 1998-09-25 | 2003-09-09 | V.I. Technologies, Inc. | Solid phase quenching systems |
| US6403359B1 (en) | 1998-09-25 | 2002-06-11 | V. I. TECHNOLOGIES, Inc. | Solid phase quenching systems |
| DE19916085A1 (de) * | 1998-10-28 | 2000-05-04 | Sonntag Hans Guenther | Verfahren zur Herstellung eines antiviralen Mittels |
| US6649170B1 (en) * | 1999-05-12 | 2003-11-18 | Statens Serum Institut | Adjuvant combinations for immunization composition and vaccines |
| WO2001046390A2 (en) * | 1999-12-20 | 2001-06-28 | Agricultural Research Council | Method of inactivating microorganisms |
| US20090017069A1 (en) | 2000-06-29 | 2009-01-15 | Lipid Sciences, Inc. | SARS Vaccine Compositions and Methods of Making and Using Them |
| AUPQ846900A0 (en) * | 2000-06-29 | 2000-07-27 | Aruba International Pty Ltd | A vaccine |
| US7439052B2 (en) | 2000-06-29 | 2008-10-21 | Lipid Sciences | Method of making modified immunodeficiency virus particles |
| US7407662B2 (en) * | 2000-06-29 | 2008-08-05 | Lipid Sciences, Inc. | Modified viral particles with immunogenic properties and reduced lipid content |
| US7407663B2 (en) * | 2000-06-29 | 2008-08-05 | Lipid Sciences, Inc. | Modified immunodeficiency virus particles |
| AU2002322284A1 (en) | 2001-06-25 | 2003-01-08 | Lipid Sciences, Inc. | Systems and methods using multiple solvents for the removal of lipids from fluids |
| US6991727B2 (en) | 2001-06-25 | 2006-01-31 | Lipid Sciences, Inc. | Hollow fiber contactor systems for removal of lipids from fluids |
| US20060060520A1 (en) | 2001-06-25 | 2006-03-23 | Bomberger David C | Systems and methods using a solvent for the removal of lipids from fluids |
| DE10144906B4 (de) * | 2001-09-12 | 2013-11-28 | Novartis Vaccines And Diagnostics Gmbh | Verfahren zur großtechnischen Herstellung von Impfstoffen |
| AU2002258268A1 (en) * | 2001-12-07 | 2003-06-17 | Genexine Co., Ltd. | Sivmac239 immunogenic plasmids and aids dna vaccine containing the same |
| US7393826B2 (en) | 2003-07-03 | 2008-07-01 | Lipid Sciences, Inc. | Methods and apparatus for creating particle derivatives of HDL with reduced lipid content |
| JP2007527387A (ja) | 2003-07-03 | 2007-09-27 | リピッド サイエンシーズ，インコーポレイテッド | 脂質含量の低下したｈｄｌの粒子誘導体を製造するための方法及び装置 |
| US8497112B2 (en) * | 2007-08-28 | 2013-07-30 | Baxter International Inc. | Method for producing viral vaccines |
| CA2797059A1 (en) * | 2010-05-03 | 2011-11-10 | Glaxosmithkline Biologicals S.A. | Novel method |
| PL2855513T3 (pl) | 2012-06-01 | 2017-05-31 | Boehringer Ingelheim Vetmedica Gmbh | Szczepionka przeciwko wirusowi Schmallenberg (SBV), sposoby wytwarzania i jej zastosowanie |
| JP6257607B2 (ja) | 2012-06-08 | 2018-01-10 | アデュロ バイオテック，インコーポレイテッド | 癌免疫療法のための組成物および方法 |
| MX361680B (es) | 2012-12-13 | 2018-12-13 | Aduro Biotech Inc | Composiciones que comprenden dinucleótidos de purina cíclicos que tienen estereoquímicas definidas y métodos para su preparación y uso. |
| SG10201708821RA (en) | 2013-04-29 | 2017-12-28 | Memorial Sloan Kettering Cancer Center | Compositions and methods for altering second messenger signaling |
| JP2016518140A (ja) | 2013-05-03 | 2016-06-23 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Ｉ型インターフェロンの環状ジヌクレオチド誘導法 |
| ES2754269T3 (es) | 2013-05-18 | 2020-04-16 | Aduro Biotech Inc | Composiciones y métodos de activación de la señalización dependiente del "estimulador de los genes de interferón |
| US9549944B2 (en) | 2013-05-18 | 2017-01-24 | Aduro Biotech, Inc. | Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling |
| US10176292B2 (en) | 2013-07-31 | 2019-01-08 | Memorial Sloan-Kettering Cancer Center | STING crystals and modulators |
| JP5865942B2 (ja) | 2014-04-16 | 2016-02-17 | 三菱電機株式会社 | 内燃機関のシリンダ吸入空気量推定装置および推定方法 |
| CA2979215A1 (en) | 2015-03-10 | 2016-09-15 | Aduro Biotech, Inc. | Compositions and methods for activating "stimulator of interferon gene"-dependent signalling |
| WO2018009466A1 (en) | 2016-07-05 | 2018-01-11 | Aduro Biotech, Inc. | Locked nucleic acid cyclic dinucleotide compounds and uses thereof |
| UY37695A (es) | 2017-04-28 | 2018-11-30 | Novartis Ag | Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo |
| EP3714039B1 (en) | 2017-11-22 | 2025-03-12 | HDL Therapeutics, Inc. | Methods for priming fluid circuits of a plasma processing system |
| AU2018396009A1 (en) | 2017-12-28 | 2020-07-16 | Hdl Therapeutics, Inc. | Methods for preserving and administering pre-beta high density lipoprotein extracted from human plasma |
| CN111629751B (zh) | 2018-01-22 | 2025-02-21 | 美国政府(由卫生和人类服务部的部长所代表) | 广泛保护性灭活流感病毒疫苗 |
| US11643641B2 (en) * | 2021-03-04 | 2023-05-09 | Malireddy S. Reddy | Prevention of viral transmission by naked genetic material |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1617457A1 (de) * | 1966-12-16 | 1972-04-20 | Erba Carlo Spa | Verfahren zur Stabilisierung von Zubereitungen interferierender Virusprodukte |
| US4036952A (en) * | 1973-02-24 | 1977-07-19 | Bayer Aktiengesellschaft | Ethyleneimine inactivated microorganisms |
| DE2321951C2 (de) * | 1973-05-02 | 1975-05-07 | Behringwerke Ag, 3550 Marburg | Verfahren zur Herstellung einer Diphtherie-Vaccine |
| US4086134A (en) * | 1973-09-18 | 1978-04-25 | University Of Glasgow | Method for preparation of vaccine against feline leukemia |
| GB1503388A (en) * | 1975-07-01 | 1978-03-08 | Inverni Della Beffa Spa | Pharmaceutically active complexes and pharmaceutical compositions containing them |
| US4452734A (en) * | 1980-02-11 | 1984-06-05 | Merck & Co., Inc. | Herpes subunit vaccine |
| US4481189A (en) * | 1982-04-14 | 1984-11-06 | New York Blood Center Inc. | Process for preparing sterilized plasma and plasma derivatives |
| US4645666A (en) * | 1982-06-08 | 1987-02-24 | The Regents Of The University Of California | Vaccine for bluetongue disease employing platinum compounds |
| US4530831A (en) * | 1982-11-02 | 1985-07-23 | Akzo N.V. | Infectious Bursal Disease vaccine |
| US4806350A (en) * | 1986-04-18 | 1989-02-21 | Norden Laboratories, Inc. | Vaccine formulation |
| EP0250128A3 (en) * | 1986-06-18 | 1988-06-08 | American Registry of Pathology | Novel virus isolated from patients with aids |
| DE3707987A1 (de) * | 1987-03-12 | 1988-09-22 | Behringwerke Ag | Inaktivierung von human immunodeficiency virus (hiv) in proteinhaltigen loesungen durch phenole |
| GB8906794D0 (en) * | 1989-03-23 | 1989-05-10 | Carroll Noel | Preparation of vaccines |
-
1991
- 1991-05-17 GB GB919110808A patent/GB9110808D0/en active Pending
-
1992
- 1992-05-15 DE DE69227400T patent/DE69227400T2/de not_active Expired - Fee Related
- 1992-05-15 AT AT92304422T patent/ATE172642T1/de not_active IP Right Cessation
- 1992-05-15 EP EP92304422A patent/EP0514199B1/en not_active Expired - Lifetime
- 1992-05-15 IN IN294MA1992 patent/IN174080B/en unknown
- 1992-05-15 CA CA002068817A patent/CA2068817A1/en not_active Abandoned
- 1992-05-15 AU AU16340/92A patent/AU652447B2/en not_active Ceased
- 1992-05-15 SG SG1996004956A patent/SG49763A1/en unknown
- 1992-05-15 BR BR929201848A patent/BR9201848A/pt not_active Application Discontinuation
- 1992-05-15 ES ES92304422T patent/ES2127203T3/es not_active Expired - Lifetime
- 1992-05-18 ZA ZA923607A patent/ZA923607B/xx unknown
- 1992-05-18 NZ NZ24278092A patent/NZ242780A/en not_active IP Right Cessation
- 1992-05-18 JP JP4168187A patent/JPH05328967A/ja active Pending
- 1992-05-18 KR KR1019920008346A patent/KR0149182B1/ko not_active Expired - Fee Related
- 1992-07-01 IE IE155692A patent/IE921556A1/en not_active IP Right Cessation
-
1996
- 1996-10-11 US US08/729,135 patent/US5698432A/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| DE69227400D1 (de) | 1998-12-03 |
| EP0514199A2 (en) | 1992-11-19 |
| AU652447B2 (en) | 1994-08-25 |
| SG49763A1 (en) | 1998-06-15 |
| EP0514199A3 (en) | 1993-11-10 |
| ZA923607B (en) | 1993-02-24 |
| ATE172642T1 (de) | 1998-11-15 |
| US5698432A (en) | 1997-12-16 |
| ES2127203T3 (es) | 1999-04-16 |
| DE69227400T2 (de) | 1999-07-01 |
| KR0149182B1 (ko) | 1998-10-15 |
| NZ242780A (en) | 1994-07-26 |
| BR9201848A (pt) | 1993-01-05 |
| JPH05328967A (ja) | 1993-12-14 |
| AU1634092A (en) | 1992-12-17 |
| EP0514199B1 (en) | 1998-10-28 |
| IE921556A1 (en) | 1992-11-18 |
| GB9110808D0 (en) | 1991-07-10 |
| KR920021162A (ko) | 1992-12-18 |
| IN174080B (enExample) | 1994-09-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU652447B2 (en) | Vaccines and methods for their production | |
| US6136321A (en) | Method of inactivating lipid-enveloped viruses | |
| US6017543A (en) | Prevention and treatment of retroviral disease | |
| RU2401665C2 (ru) | Иммуногенная композиция и способ разработки вакцины, основанной на вич, инактивированном псораленом | |
| US8506968B2 (en) | SARS vaccine compositions and methods of making and using them | |
| US20140050763A1 (en) | Modified viral particles with immunogenic properties and reduced lipid content useful for treating and preventing infectious diseases | |
| NZ553165A (en) | Vaccine composition comprising West Nile viral DNA an oil adjuvant such as squalane and optionally wetting and dispersing agents | |
| Gardner | Vaccination against SIV infection and disease | |
| US7033813B2 (en) | Inactivated vaccines for aids and other infectious diseases | |
| CA2529965C (en) | Modified viral particles with immunogenic properties and reduced lipid content useful for treating and preventing infectious diseases | |
| Race et al. | A multistep procedure for the chemical inactivation of human immunodeficiency virus for use as an experimental vaccine | |
| Race et al. | An experimental chemically inactivated HIV-1 vaccine induces antibodies that neutralize homologous and heterologous viruses | |
| on‘Macaque et al. | Protection of macaques against simian immunodeficiency virus infection with inactivated vaccines: comparison of adjuvants, doses and challenge viruses | |
| Gardner | SIV vaccines: Current status: The role of the SIV—Macaque model in AIDS research | |
| US20240335522A1 (en) | Multivalent pan-influenza vaccine | |
| AU2008201523B2 (en) | Modified viral particles with immunogenic properties and reduced lipid content useful for treating and preventing infectious diseases | |
| AU2004264842B2 (en) | Modified viral particles with immunogenic properties and reduced lipid content useful for treating and preventing infectious diseases | |
| WO1992000098A1 (en) | Methods of inducing immune response to aids virus | |
| Shuenn-jue | Immunogenicity of Adjuvanted Psoralen-Inactivated SARS-CoV-2 Vaccines and SARS-CoV-2 Spike Protein DNA Vaccines in BALB/c Mice | |
| Hostel | Efficacy and their Delivery System: A Review | |
| CA2127466A1 (en) | Feline leukemia virus vaccines | |
| Newman et al. | Characterization of Immune Responses Elicited by an Experimental Facilitated-DNA Vaccine for Human Immunodeficiency Virus Type-1 (HIV-1) | |
| Osterhaus | Development of a vaccine against AIDS: state of the art. | |
| EP0678033A1 (en) | Human aids vaccine from revertant cattle virus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |